Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
11.11.Capricor, NextCure reveal recent layoffs as they gear up for approval decision, merger
11.11.Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator lead
10.11.Beam's sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
10.11.PepGen's stock doubles as midphase muscle dystrophy data wow analysts
10.11.AstraZeneca buys partner Omniose for bacterial vaccine technology
10.11.'Flying blind': Why experts fear Treasury's China biotech investment crackdown will backfire
10.11.Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug's FDA run
10.11.AbCellera becomes latest biotech to abandon dream of developing OX40 drug
10.11.Coherus shrinks headcount 30% to narrow focus of cancer combo
09.11.Merck's MASH hopeful efinopegdutide wins in mid-stage study
09.11.When China Fits a Global Clinical Development Strategy
09.11.Recent Lisata prize Marea touts 'exciting' lipid disorder phase 2 win, mulls obesity potential
09.11.J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
09.11.Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
09.11.Spruce spins out preclinical endocrinology program into newly formed Adrenyx
09.11.AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
09.11.Sanofi-backed Windward Bio breezes toward $204M IPO to fund respiratory pipeline from China
09.11.Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor
09.11.Kyorin pens $140M deal for Japan rights to Edesa's phase 3 respiratory drug
09.11.Faeth's phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
09.11.Vir's phase 3 hepatitis delta win fuels push to eclipse Gilead
09.11.Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
09.11.Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test
07.11.Novartis' Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
06.11.Looking Beyond the First Answer Towards Delivering Impact